ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Jarosław Reguła et al.|Annals of Oncology|2012Cited by 1.5k
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Julien Taı̈eb, Qian Shi et al.|Journal of Clinical Oncology|2022Cited by 50
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 TrialsClaire Gallois, Demetris Papamichael, Qian Shi et al.|Journal of Clinical Oncology|2024Cited by 25
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.Anthony F. Shields, Timothy Iveson, Fang‐Shu Ou et al.|Journal of Clinical Oncology|2018Cited by 6
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.Elisa Fontana, Jeffrey P. Meyers, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2021Cited by 2